Living with hormone therapy: A guide for men with prostate cancer

Updated: September 2015| Due for Review: September 2018

• Adler RA. Management of osteoporosis in men on androgen deprivation therapy. [Review] Maturitas. 2011; 68(2):143-7,
• Ahmadi H;  Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. [Review] BJU International.  111(4):543-8, 2013 Apr.
• Alibhai SMH, Gogov  S, Alllibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Critical reviews in Oncology/Hematology 60 (2006) 201-215
• Azoulay L, Yin H, Benayoun S et al. Androgen-Deprivation Therapy and the Risk of Stroke in Patients With Prostate Cancer. Eur Urol. 2011
• Beard C, Stason WB, Wang Q, Manola J, Dean-Clower E, Dusek JA, Decristofaro S, Webster A, Rosenthal DS, Benson H. Effects of complementary therapies on clinical outcomes in patients being treated with radiation therapy for prostate cancer. Cancer. 2010 Aug 27
• Beck AM, Robinson JW, Carlson LE et al. Sexual intimacy in heterosexual couples after prostate cancer treatment: What we know and what we still need to learn. Urol Oncol. 2008 Feb 22. [Epub ahead of print]
• Beer TM1, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Jul 31;371(5):424-33.
• Bekelman, J.et al. (2015). Effectiveness of Androgen-Deprivation Therapy and Radiotherapy for Older Men With Locally Advanced Prostate Cancer. Journal of Clinical Oncology.
• Bosset P-O, Albiges L, Seisen T, de la Motte Rouge T, Phé V, Bitker M-O, et al. Current role of diethylstilbestrol in the management of advanced prostate cancer. BJU Int. 2012 Dec;110(11 Pt C):E826–9.
• Brungs D;  Chen J;  Masson P et al. Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis. [Review]. Prostate Cancer & Prostatic Diseases.  17(2):105-11, 2014 Jun
• Burns-Cox N, Basketter V, Higgins B et al. Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer. International Journal of Urology 2002; 9(8): 431-434.
• Cabot RC, Harris NL, Rosenberg ES, Shepard J-AO, Cort AM, Ebeling SH, et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187–97.
• Carlson LE, Bultz BD. Mind-body interventions in oncology. Curr Treat Options Oncol. 2008 Jun;9(2-3):127-34. Epub 2008 Aug 13
• Dason S;  Allard CB;  Wang JG et al.  Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice. [Review] Canadian Journal of Urology.  21(2 Supp 1):28-36, 2014 Apr.
• Di Lorenzo G, Autorino R, Perdona S et al. Management of gynaecomastia in patients with prostate cancer: a systematic review. Lancet Oncology 2005; 6: 972-79.
• Drudge-Coates L. Bone health: the effect of androgen deprivation therapy in prostate cancer patients. International Journal of Urological Nursing 2007; 1(1): 18-26.
• Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol 2007; 177:17-24
• Elkins G, Marcus J, Stearns V et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. Journal of Clinical Oncology. 2008;26(31):5022-6.
• Elliott s, Latini DM, Walker LM et al. Androgen deprivation therapy for prostate cancer: Recommendations to improve patient and partner quality of life. J Sex Med. 2010. DOI: 10.1111/j.1743-6109.2010.01902.x
• EMC accessed 2014 https://www.medicines.org.uk/emc/
• Foley E, Baillie A, Huxter M, Price M, Sinclair E. Mindfulness-based cognitive therapy for individuals whose lives have been affected by cancer: a randomized controlled trial. J Consult Clin Psychol. 2010 Feb;78(1):72-9.
• Fradet Y, Egerdie B, Andersen M, et al. Tamoxifen as Prophylaxis for Prevention of Gynaecomastia and Breast Pain Associated with Bicalutamide 150 mg Monotherapy in Patients with Prostate Cancer: A Randomised, Placebo-Controlled, Dose–Response Study. European Urology. 2007;52:106–115
• Gardner JR1, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol. 2014 Feb 1;32(4):335-46. doi: 10.1200/JCO.2013.49.5523
• Grossmann M.  Hamilton EJ.  Gilfillan C.  Bolton D.  Joon DL.  Zajac JD. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. [Review] Medical Journal of Australia. 2011; 194(6):301-6
• Gruca D, Bacher P & Tunn U. Safety and tolerability of intermittent androgen deprivation therapy: A literature review. International Journal of Urology. 2012;19:614-625
• Haliloglu A, Baltaci S,  and Yaman O. Penile Length Changes in Men Treated With Androgen Suppression Plus Radiation Therapy for Local or Locally Advanced Prostate Cancer. The Journal of Urology 2007:77,128-130
• Haseen F, Murray LJ, Cardwell CR, O'Sullivan JM, Cantwell MM. The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer Surviv. 2010;4(2):128-39
• Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003; 61(Suppl 2A): 32-38.
• Higano CS1. Intermittent versus continuous androgen deprivation therapy. J Natl Compr Canc Netw. 2014 May;12(5):727-33.
• Irani J, Salomon L, Oba R et al. Effi cacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 2010;11:147-154.
• Iversen P, Karup C, van der Meulen E. Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide. Prostate Cancer and Prostatic Diseases. (2011);14:184–190.
• Jamadar RJ, Winters MJ & Maki PM. Cognitive changes associated with ADT: a review of the Literature. Asian Journal of Andrology. 2012;14:232–238
• Jones JM, Kohli M & Loprinzi CL. Androgen deprivation therapy-associated vasometer symptoms. Asian J androl. 2012;14(2):193-197.
• Karling P, Hammar M, Varenhorst E. Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol. 1994 Oct;152(4):1170-3.
• Keogh JWL & MacLeod RD. Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: A systematic review. Journal of pain and symptom management. 2012;43(1):93-110.
• Klotz L, Boccon-Gibod L, Shore N D, Andreou C  P, Bo-Eric C, Jensen J, Olesen T K, Schroder F H. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-bale, parallel-group phase III study in patients with prostate cancer. BJU International. 2008 102, 1531-1538.
• Kumar S, Shelley M, Harrison C et al. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD006019
• Kunath F, Grobe HR, Rucker G et al. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer (Review). The Cochrane Collaboration 2014.
• Lee MS, Kim K-H, Shin B-C et al. Acupuncture for treating hot flushes in men with prostate cancer: a systematic review. Support Care Cancer. 2009;17:763–770
• Loblaw DA, Virgo KS, Nam R et al. Initial hormonal management of androgen-sensitive Metastatic, recurrent, or progressive prostate cancer – 2006 update of an American Society of Clinical Oncology practice guideline. Journal of Clinical Oncology 2007; 25(12): 1596-1605.
• Lukka H, Waldron T, Klotz L, Winquist E, Trachtenberg J. Maximal androgen blockade for the treatment of metastatic prostate cancer – a systematic review. Curr Oncol. 2006 Jun; 13(3): 81-93. Cited in castrate resistant
• Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncology. 2012;13(3):309-18.
• McGinty HL; Phillips KM; Jim HS et al. Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. [Review]. Supportive Care in Cancer. 22(8):2271-80, 2014 Aug.
• Medicines and Healthcare products Regulatory Agency. UKPAR Black Cohosh, UK Public Assessment Report, Available at: http://www.mhra.gov.uk/SearchHelp/GoogleSearch/index.htm?q=black%20cohosh%20mhra. Accessed September 2012
• Mohile SG, Mustian K, Bylow K, Hall W, Dale W. Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol 2009 Jun;70(3):235-55.
• Moraska AR, Atherton PJ, Szydlo DW, et al. Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB. J Support Oncol 2010 May-Jun;8(3):128-32
• Mottet, P.J. Bastian, J. Bellmunt, Guidelines on prostate cancer EAU 2014
• Mottet, Prayer-Galetti, Hammerert Pet al. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int. 2006; 98: 20-27
• National Clinical Guideline Centre (2012) Osteoporosis: fragility fracture risk. Osteoporosis: assessing the risk of fragility fracture (full NICE guideline). . Clinical guideline 146. National Institute for Health and Care Excellence. www.nice.org.uk
• National Institute for Health and Clinical Excellence. 2014. Prostate cancer: diagnosis and treatment.
• National Osteoporosis Society. Osteoporosis: causes, prevention and treatment. 2001. Bath: NOS.
• Nelson CJ, Lee JS, Gamboa MC et al. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 2008;113:1097-106.
• Nguyen PL1, Je Y, Schutz FA et al Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011 Dec 7;306(21):2359-66
• NHS Choices. Effects of alcohol. Available from: http://www.nhs.uk/Livewell/alcohol/Pages/Effectsofalcohol.aspx. Accessed 08 March 2011
• Oliffe J. Embodied masculinity and androgen deprivation therapy. Sociology of Health and Illness 2006; 28(4): 410-432.
• Planas J, Morote J, Orsola A, Salvador C, Trilla E, Cecchini L et al. The relationship between daily calcium intake and bone mineral density in men with prostate cancer. British Journal of Urology. 2007; 99: 812-816
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med. 2013;368(2):138-148.
• Saylor PJ1, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2013 Jan;189(1 Suppl):S34-42
• Schmitt B, Bennett C, Seidenfeld J et al. Maximal androgen blockade for advanced prostate cancer. Cochrane Database of Systematic Reviews 1999, Issue 2.
• Schroder F, Crawford ED, Axcona K, et al. Androgen deprivation therapy: Past, present and future. BJU International. 2012;109(6):1-12
• Segal RJ, Reid RD, Courneya KS et al. Resistance training in men receiving androgen deprivation for prostate cancer. J Clin.Oncol 2003; 21:1653-9.
• Shore ND, Abrahamsson P-A, Anderson J, Crawford ED, Lange P. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis. 2013 Mar;16(1):7–15
• Smith MR, Egerdie B, Toriz NH et al. Denosumab in me receiving androgen-deprivation therapy for prostate cancer. N Eng J Med. 2009;361(8):745-755.
• Storey DJ, McLaren DB, Atkinson MA, et al. Clinically relevant fatigue in men with hormonesensitive prostate cancer on long-term androgen deprivation therapy. Annals of Oncology. 2012; 23:1542–1549.
• Thorsen L, Courneya KS, Stevinson C, Fossa SD. A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants. Support Care Cancer. 2008;16:987-997.
• Viani GA, Bernardes da Silva LG, Stefano EJ. Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: tamoxifen or radiotherapy? Int J Radiat Oncol Biol Phys. 2012;83(4):e519-24.
• Warde P, Mason M, Ding K et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. The Lancet, Early Online Publication, 3 November 2011 doi:10.1016/S0140-6736(11)61095-7
• Widmark A, Klepp O, Solberg A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. The Lancet 2008, Volume 373, Issue 9660, Pages 301 - 308, 24
• Wilkins A, Shahidi M, Parker C, Gunapala R, Thomas K, Huddart R, et al. Diethylstilbestrol in castration-resistant prostate cancer. BJU Int. 2012 Dec 1;110(11b):E727–35.
• Wolff JM;  Abrahamsson PA;  Irani J et al. Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?. [Review] BJU International.  114(4):476-83, 2014 Oct.
• Yousaf O, Stefanopoulou E, Grunfeld EA et al. A randomised controlled trial of a cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN): trial protocol. BMC Cancer. 2012;12:230.

This booklet is for men who are having hormone therapy for prostate cancer, their partners and families. It describes the different types of hormone therapy, how they work and what the treatment involves. It includes information on the possible side effects men may experience and suggests ways to help manage these.